Health Economics›Colorectal cancer›Advanced or metastatic disease second or third-line therapy

Advanced or metastatic disease second or third-line therapy

Colorectal cancer · 10 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
FOLFIRI and Cetuximab Variant #01	BRAF	R 81 374	14d	—	5.9 mo	11	R 371 679 PFS proxy	2
Trastuzumab deruxtecan monotherapy Variant #01	ERBB2	R 81 019	21d	—	~13.6 mo	~2	~R 162 039 PFS proxy · indirect	2
Pertuzumab and Trastuzumab Variant #01	ERBB2	R 78 133	21d	—	—	~2	~R 104 177 indirect	—
Irinotecan and Cetuximab Variant #01	BRAF	R 55 838	14d	2.0 mo	5.9 mo	3	R 82 477 PFS proxy	4
Dabrafenib, Trametinib, Panitumumab Variant #01	BRAF	R 51 650	14d	—	—	~2	~R 103 299 indirect	—
Irinotecan, Vemurafenib, Cetuximab Variant #01	BRAF	R 38 594	14d	4.2 mo	—	2	R 77 188 PFS proxy	1
Binimetinib, Encorafenib, Cetuximab Variant #01 Partial	BRAF	R 30 708	7d	—	9.2 mo	3	R 42 519 PFS proxy	2
Encorafenib and Cetuximab Variant #01 Partial	BRAF	R 30 708	7d	—	8.9 mo	3	R 42 519 PFS proxy	2
Lapatinib and Trastuzumab Variant #04	ERBB2	R 15 652	42d	~2.6 mo	~14.0 mo	~3	~R 32 897 PFS proxy · indirect	2
Tucatinib and Trastuzumab Variant #01 Partial	ERBB2	R 14 059	21d	—	—	~3	~R 18 745 indirect	—

10 of 10 regimens shown